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Stroke is one of the most common causes of death and disability in the world and creates a significant social and economic burden for our society.[@ref1] As we know, while stroke could be divided into two types, ischemic and hemorrhagic, the ischemic stroke accounts for approximately 80% of them.[@ref2][@ref3] The majority of ischemic strokes are caused by a large artery occlusion due to thromboembolism.[@ref4] Currently, more and more attention has been paid to the role of inert gases such as xenon, helium and argon in the protection of nerve function. All of them possess biological effects that have shown to be neuroprotective in pre-clinical models of ischemic stroke.[@ref5] Therefore we can focus on their beneficial effects to solve clinical problems caused by ischemia-induced neuronal death.[@ref6]

Similar to helium and other noble gases, argon was investigated for its therapeutic properties, as early as in 1930s.[@ref5] Argon has a lot of advantages compared to other medical gases. It is more abundant than other noble gases and generates inexpensive costs; what\'s more, the lack of hypnotic effects in normobaric pressures allows it to become a useful therapeutic agent for many conditions including cerebral ischemia. The effects of argon were tested in different *in vitro* and *in vivo* models. Regarding cell-culture based research, injury of neuronal cells by deprivation of glucose and oxygen is a frequently used model, investigating neuroprotective properties of gaseous molecules.[@ref7] So, in order to explore the practicability of treatment. we will discuss the impact of argon on stroke injury and the potential mechanisms of neuroprotection on the basis of experimental and clinical studies in this article.
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As for animal experiments, we have successfully established animal models of hemorrhagic and ischemic stroke, especially ischemic, and applied the gas of argon to treat the subjects after stroke insult. The researchers detect the effects of argon on stroke and explore the potential mechanisms by which this gas can protect the nervous system.[@ref8] As everyone knows, animal experiments also belong to basic medical and preclinical research and most of them were aimed to investigate the mechanism of objective gas on neurological status following stroke. Now we find that conclusions of these studies are different to a great extent, and we think this is owing to different experimental conditions and methods. We will analyze several recent experimental studies related to this gas for stroke treatment in this paper (**[Table 1](#T1){ref-type="table"}**), and then summarize the outcomes. In the in vitro model of oxygen-glucose deprivation (OGD), it was found that 75% vol/vol argon protected against the cell death of neurons, while however neon and krypton had no effect, and helium exacerbated cell death.[@ref9] In a hippocampal organotypic slice subjected to OGD, according to studies, argon (at doses of 25, 50 or 75% vol) was neuroprotective, and this protection could be maintained with a delayed treatment.[@ref10] An *in vivo* transient rat middle cerebral artery occlusion (MCAO) study showed that 50% vol argon administration for 1 hour in ischemia could reduce infarct volume and neurological deficit.[@ref11] In brain slices, treatment of argon in different vol (37%, 50% and 75% vol) in post-OGD could produce a reduction in cell death.[@ref12] Recently, some studies have shown that in a model of perinatal asphyxia, argon treatment (70% vol) post-hypoxic-ischemic (HI) could reduce infarct volume associated with an increase in the anti-apoptotic protein Bcl-2.[@ref13]
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According to the above experiments, the promising preclinical results of argon applied following ischemia, suggest that argon could be further examined as a potential neuroprotective gas for ischemic stroke in the clinical setting, which we believe it would succeed.
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The underlying mechanism of the neuroprotective function of argon has not been fully elucidated. However, there is ample evidence to show that argon activates the γ-aminobutyric acid (GABA) receptor by acting at the benzodiazepine binding site,[@ref14] and GABA receptor agonists can confer neuroprotection after ischemia via the phosphoinositide 3-kinase pathway[@ref15] or by abating the phosphorylation of the NR2A subunit of the N-methyl D-aspartic acid (NMDA) receptor.[@ref16] Here we will discuss both pathways of how argon protects neurons. Firstly, as we all know, the survival or death of neurons is determined by the balance between pro-survival and pro-apoptosis signals. The Akt (protein kinase B) serine/threonine kinases, as the downstream of phosphatidylinositol 3-kinase (PI-3K), are important mediators of cell survival in brain ischemia. The c-Jun N-terminal kinase (JNK) pathways are stress-activated mitogen-activated protein kinase modules which can be stimulated by brain ischemia. Therefore, one of the mechanisms of cell survival may be the inhibition of the activity of stress-activated kinase cascades. A lot of pro-apoptotic proteins have already been identified as direct Akt substrates, including glycogen synthase kinase 3 (GSK-3), BAD, caspase-9, and apoptosis signal-regulating kinase 1 (ASK1), which were suppressed upon phosphorylation by Akt.[@ref17][@ref18][@ref19][@ref20] Specifically, by increasing Akt activity, the suppression of the ASK1-mitogen-activated extracellular signal-regulated kinase (MEK)-JNK pathways dependent on phosphorylation of serine 83 of ASK1 would be activated,[@ref20][@ref21] otherwise ASK1 would phosphorylate and activate mitogen-activated protein kinase kinase 4 (MKK4) or MKK7 which in turn induce JNK kinase activities.[@ref15] So we believe that argon can exerted neuroprotective effect *via* PI-3K/Akt pathway, which could inhibit the ASK1-JNK cascade, by activating the GABA receptor.

Secondly, glutamate, as a major excitatory neurotransmitter in the central nervous system (CNS), is frequently researched because it is related to the development of cerebral ischemia induced cell death. Glutamate receptors are mainly classified into two groups: metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs). The ionotropic glutamate receptors have been divided into three classes pharmacologically: NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate (KA) receptors. The NMDA receptor acts as a ligand-gated calcium channel, which plays an important role in neuronal development, addiction, learning and memory.[@ref22] Over-excessive release of glutamate will cause over-activation of glutamate receptors, mainly NMDA-type, and subsequent calcium overload, all known as excitotoxicity, and then will activate calcium-dependent signaling cascade reactions of postsynaptic neurons that eventually leads to neuronal death.[@ref23] According to the study by other researchers, the NMDA receptors are formed by two classes of subunits, a principal NR1 subunit and modulatory NR2 subunits (NR2A--NR2D).[@ref24] NMDA receptors are phosphorylated on tyrosine residues of NR2 subunits, especially NR2A and NR2B.[@ref25] The protective effect of nerve function is mediated by argon through intervening in the above two pathways (**[Figure 1](#F1){ref-type="fig"}**).
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A decade of investigation on the effects of xenon has led to a clinical trial that may yet change clinical care of perinatal asphyxia. The findings of Loetscher and his colleagues should encourage the pursuit of argon as a neuroprotective alternative/supplement to xenon.[@ref26] The potential value for the clinical application of argon needs to be further explored through tests of clinical safety and translational research. According to the data of the current research, there is an increasing amount of evidence that at the vol of 50-70% argon may have potentially neuroprotective and therapeutic properties and be beneficial for preventing brain injury, by protecting neurons in the brain through above two pathways. Although there is insufficient clinical evidence that argon can effectively treat stroke. Future studies should focus on clinical experiments to further explore the use method, dosage and adverse reactions of argon gas. We believe that the argon will open up a new method to protect nervous system.
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